Immuron Ltd (IMRN) Stock Analysis
Verdict: WATCH (do not buy)
US PROIBS commercialization expands commercial reach, but a 62% news spike leaves high risk of near-term pullback on cash-burning profile.
Investment score: 46/100
Analysis as of
Is Immuron Ltd stock worth reviewing? AI model thesis
The AI model rates Immuron as HOLD following a 62.2% single-day surge driven by its U.S. PROIBS distribution agreement. Strong liquidity (8.04x current ratio, zero debt) provides a 30-month runway, but persistent operating losses (-4.63M AUD FY2026) favor waiting for technical consolidation.
7-factor investment score
- Valuation: 40/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 30/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 35/100 (weight 15%)
Immuron Ltd opportunities and risks
What speaks for IMRN
- Exclusive U.S. distribution agreement for PROIBS expands addressable market
What speaks against IMRN
- Commercial execution risk in U.S. gut-health expansion
Peers and competitors
Frequently asked questions about Immuron Ltd (IMRN)
Is IMRN stock a good investment?
The cached TradeMates AI model rates Immuron Ltd as WATCH (do not buy) with an investment score of 46/100. The AI model rates Immuron as HOLD following a 62.2% single-day surge driven by its U.S. PROIBS distribution agreement. Strong liquidity (8.04x current ratio, zero debt) provides a 30-month runway, but persistent operating losses (-4.63M AUD FY2026) favor waiting for technical consolidation. This is algorithmic model output, not personal investment advice.
Is IMRN stock a buy?
The TradeMates model verdict for IMRN is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.